These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 8470049)

  • 1. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
    Herbert JM; Bernat A; Barthelemy G; Dol F; Rinaldi M
    Thromb Haemost; 1993 Mar; 69(3):262-7. PubMed ID: 8470049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
    Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit.
    Herbert JM; Bernat A; Sainte-Marie M; Dol F; Rinaldi M
    Thromb Haemost; 1993 Mar; 69(3):268-71. PubMed ID: 8470050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis.
    Cohen ML; Robertson DW; Bloomquist WE; Wilson HC
    J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.
    Rinaldi-Carmona M; Congy C; Santucci V; Simiand J; Gautret B; Neliat G; Labeeuw B; Le Fur G; Soubrie P; Breliere JC
    J Pharmacol Exp Ther; 1992 Aug; 262(2):759-68. PubMed ID: 1501121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SR 121787, a new orally active fibrinogen receptor antagonist.
    Savi P; Badorc A; Lalé A; Bordes MF; Bornia J; Labouret C; Bernat A; de Cointet P; Hoffmann P; Maffrand JP; Herbert JM
    Thromb Haemost; 1998 Sep; 80(3):469-76. PubMed ID: 9759629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries.
    Bush LR
    J Pharmacol Exp Ther; 1987 Feb; 240(2):674-82. PubMed ID: 3806419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic and antiplatelet activities of Korean red ginseng extract.
    Jin YR; Yu JY; Lee JJ; You SH; Chung JH; Noh JY; Im JH; Han XH; Kim TJ; Shin KS; Wee JJ; Yun YP
    Basic Clin Pharmacol Toxicol; 2007 Mar; 100(3):170-5. PubMed ID: 17309520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.